Resectable Liver Metastases From Colorectal Cancer
Conditions
Interventions
Patients receive FOLFOX regimen or XELOX (oxaliplatin plus capecitabin) and MoAb as neoadjuvant protocol
Sponsors
Epidemiological and Clinical Research Information Network
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1,Histologically confirmed colorectal cancer 2,KRAS mutation status was determined 3,Resectable liver metastases with or without lymphnode metastases 4,No extrahepatic disease 5,No prior chemotherapy , immunotherapy and radiotherapy except adjuvant chemotherapy if ended >=6 months before study entry 6,No prior radiofrequency ablation or surgery for liver metastases 7,No prior radiotherapy for liver metastases 8,ECOG performance status <=1 9,Adequate hematological, renal and liver function 10,Written informed consent
Exclusion criteria
Exclusion criteria: 1,Serious myelosuppression 2.Serious infection 3,Large quantity of abdominal or pleural effusion 4,cardiovascular disease, complication 5,sensory alteration or paresthesia interfering with function 6,No brain or bone metastasis, active double cancer 7,No hypersensitivity for test drugs 8,Serious pulmonary disease 9,Liver cirrhosis 10,Multiple cancer patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| anti-tumor effect overall survival R0 resection rate | — |
Countries
Japan
Outcome results
None listed